Sign Up
OverviewAPI
The law firm Bragar Eagel & Squire, P.C. is exploring claims against Axsome Therapeutics, Inc. on behalf of long-term shareholders post a class action complaint. Axsome, a U.S. biopharmaceutical firm, encountered hurdles with its AXS-07 NDA application for migraine treatment, resulting in a decline in stock value. The FDA's issuance of a Complete Response Letter on May 2, 2022, highlighted critical CMC issues.

Ask a question